PRZOOM - /newswire/ -
Holmes Chapel, Cheshire, United Kingdom, 2012/02/02 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology - PRECOS.co.uk.
Preclinical Oncology Services Limited will be showcasing several new platforms for pre-clinical oncology research at two leading shows: Cancer Targets & Therapeutics, Las Vegas, February 27th - 28th and AACR, Chicago, March 31st - April 4th 2012.
PRECOS leads the way in providing robust models, validated against today’s Standard Of Care agents to enable pre-clinical in vitro and in vivo testing of the next generation of oncology candidate drugs. The International Agency for Research on Cancer (IARC) forecasts that by 2030 there will be over 26 million new cases and 17 million deaths per year from cancer. PRECOS will be launching several new cutting-edge services at the North American shows which support target validation and drug screening early in the research process for anti-cancer activity. The company provides expertise, specialism and innovation to small to medium biotechnology companies and the new platforms will support new and existing projects going forward.
At the shows PRECOS will highlight how it can deliver a customised screening platform either in 2-D or 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities. Cell lines created from patient primary tissue that “never see plastic” are selected based their true characteristics as cancer cells, instead of their ability to survive in vitro.
Dr Neil Rotherham, chairman of PRECOS comments,“The new service lines demonstrate our commitment to offer a world-class service and the platforms provide significant benefits to clients. We are excited to talk to existing and potential clients from around the world at these leading events to demonstrate the breadth of solutions we can offer them for their oncology research and development needs.”
The 2012 3rd Cancer Targets & Therapeutics Conference examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development. The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research. PRECOS’ full service offering will be highlighted at Cancer Targets & Therapeutics 2012 and on booth #4306 at AACR 2012. For further information please call +44 (0)870 166 6234, email enquiries[.]precos.co.uk or visit precos.co.uk.
About PRECOS Ltd
PRECOS Ltd (precos.co.uk) is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade.